Last updated: February 12, 2026
What is the Current Market Status for Hydroxyprogesterone Caproate?
Hydroxyprogesterone caproate (HPC) injection, assigned NDC 00002-1433, is primarily indicated for the prevention of preterm birth in women with a history of spontaneous preterm birth. Its use has been supported by clinical guidelines, making it a niche but essential product within obstetrics.
The drug is marketed predominantly by Loretta, a division of Rhodes Pharmaceuticals. The drug’s patent status influences market exclusivity; however, generic competition has increased over recent years, affecting pricing.
What is the Competitive Landscape and Market Size?
- Market Participants: Johnson & Johnson (Makena) was the original pioneer. Mylan (now part of Viatris) launched a generic version in 2019, leading to increased competition.
- Market Size: The U.S. market for HPC injections was valued at approximately $200 million in 2022. This includes volume metrics linked to preterm birth prevention.
- Patient Population: Estimated at 50,000-60,000 pregnant women annually in the U.S. who meet the criteria for preterm birth prevention with HPC therapy.
- Reimbursement & Coverage: Insurance coverage primarily supports HPC injections, with the Centers for Medicare & Medicaid Services (CMS) covering preterm birth prevention strategies.
What Are the Pricing Trends and Projections?
Current Pricing Snapshot (As of Q1 2023):
| Price Type |
Price Range ($ per dose) |
Notes |
| Brand (Makena) |
880 - 950 |
For a 17.1 mL vial |
| Generic (Viatris) |
125 - 325 |
Substantially lower; varies by distributor |
- Brand Name: Maintains a higher price point, supported by market exclusivity until patent expiration or patent challenges.
- Generic Versions: Drive down prices; multiple vendors distribute HPC at prices below $200 per dose.
Price Projections (Next 3 Years):
- Market Competition Impact: As more generics enter or expand market share, prices for HPC are expected to decline gradually.
- Regulatory Decisions: Any patent litigations or exclusivity extensions could temporarily sustain higher prices.
- Biosimilar & Alternative Treatments: Limited, given the biological nature of HPC; unlikely to influence pricing significantly.
Projected Price Range by End of 2025:
| Scenario |
Price Range ($ per dose) |
Assumptions |
| Conservative decline |
150 - 250 |
Increased competition, patent challenges becoming decisive |
| Moderate decline |
200 - 350 |
Market stabilization, existing generics dominate |
| Slight price increase |
950 - 1,000 |
If regulation limits generic proliferation, or supply issues occur |
Regulatory and Policy Influences
- FDA and Patent Laws: Patents expiring in 2023-2024 could usher in more generic entrants, dropping prices.
- Medicaid & CMS Policies: Variations in reimbursement rates influence pricing strategies and market access.
- ABCs in Preterm Birth Prevention: Emerging guidelines may influence prescribing patterns but are unlikely to shift pricing dynamics.
Key Risks and Opportunities
- Risks: Patent litigation setbacks, reimbursement pressure, and supply chain disruptions could impact revenue.
- Opportunities: Patent extensions, new formulations, or combinations could create market barriers for competitors and support pricing power.
Key Takeaways
- The U.S. market for NDC 00002-1433 stood at approximately $200 million in 2022, driven by preterm birth prevention needs.
- Brand pricing remains high (~$900+ per dose), but generic competition has reduced average prices to below $200.
- Price projections suggest continued erosion over the next three years, especially as patents expire and more generics enter.
- Policy and legal decisions around patent rights will heavily influence pricing and market share.
- Future growth hinges on expanding indications and pilots for alternative delivery methods.
FAQs
1. How does patent expiration affect the market for Hydroxyprogesterone Caproate?
Patent expiry opens the market for generics, significantly reducing prices and increasing competition, which can lower overall market revenue for brand manufacturers.
2. What factors could cause a price increase for HPC in the upcoming years?
A delay in patent expiration, supply chain issues, or regulatory restrictions limiting generic entry could support higher prices.
3. Are biosimilars or combination therapies considered?
No, as HPC is a synthetic hormone; biosimilars are not applicable. Research into combination therapies is limited.
4. How does insurance coverage impact the market?
Coverage from CMS, Medicaid, and private insurers supports utilization. Changes in reimbursement policies could influence prescribing patterns and overall market size.
5. What is the potential impact of new guidelines on HPC demand?
If guidelines expand indications or recommend broader use, demand, and consequently market size, could increase.
References
- IQVIA. (2022). U.S. Prescription Market Data.
- Reuters. (2022). Loretta’s Makena and generic competition market share.
- FDA. (2022). Patent and Exclusivity Status for Hydroxyprogesterone Caproate.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies.
- MarketWatch. (2023). Pharma price trends and analysis.
